Capricor Therapeutics gains traction with impending treatment data reveal in Czechia
The biotech company will be revealing 3-year safety data on its primary drug for Duchenne muscular dystrophy next week
Rowan Dunne· Oct 4, 2024
Shares of Capricor Therapeutics Inc (NASDAQ: CAPR) are up by about 27 per cent this Friday after the biotech company announced that it would soon be presenting data on its top drug candidate.
The rare disease treatment developer will be educating people about its deramiocel drug at the Annual Congress of the World Muscle Society in European city of Prague next week. It is used to treat a rare variation of muscular dystrophy designated as “Duchenne’s” that is primarily diagnosed in males.
Duchenne muscular dystrophy (DMD) is distinct from its standard counterparts due to its early onset and quick progression. It causes rapid muscle deterioration and premature death. Those who are diagnosed when they are young generally only live into their late twenties while people with other variations can be around for decades longer.
There are approximately 17,500 men and boys in the United States who suffer from the condition and around 200,000 globally.
Capricor also aims to use its drug to treat individuals suffering from DMD-cardiomyopathy — a heart disease associated with the muscular ailment.
“The results of this study are foundational to our recent announcement to commence the filing of a Biologics License Application for potential approval of deramiocel to treat patients with DMD-cardiomyopathy and continue to support the long-term impact of deramiocel for the treatment of DMD.”
This stock, listed on the Russell 2000 Index (INDEXRUSSELL: RUT), has been absolutely soaring over the past couple of weeks. If only we had known earlier.
You don't need a PhD in biochemistry 🤓 to find opportunities in #biotech stocks sometimes being able to spot a simple chart pattern 📈will be all you need $CAPR shares up 482 % from Dec 10 post 👀
$CAPR #biotechnology company currently in late-stage clinical development for treating Duchenne muscular dystrophy big gap to fill 👀 #stocks #biotech $SRPT $SLDB $TRDA $PEPG
Read more: Breath Diagnostics takes aim at lung cancer with One Breath
Read more: Breath Diagnostics pioneers novel lung cancer breath test
Capricor has a Japanese companion
In 2022, the biotech company initiated a collaboration with the drug manufacturer Nippon Shinyaku Co., Ltd. (TYO: 4516).
Nippon has a Japanese and American team that are supporting broad commercialization of Capricor’s DMD drug.
In mid-September the two companies announced their intention to expand distribution into Europe. Nippon bought up US$15 million worth of Capricor stock when this revealed.
“Our expanded partnership with Nippon Shinyaku into the European region marks a pivotal moment for Capricor as we work together to bring deramiocel to DMD patients worldwide,” Linda Marbán, Capricor CEO, said Sept. 17.
rowan@mugglehead.com
